The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?

Abstract

CONTEXT: Several paradoxical cases of infliximab-induced or-exacerbated psoriatic lesions have been described in the recent years. There is disagreement regarding the need to discontinue infliximab in order to achieve the resolution of these adverse cutaneous reactions specifically in inflammatory bowel disease (IBD) patients. OBJECTIVE: To systematically review the literature to collect information on IBD patients that showed this adverse cutaneous reaction, focusing mainly on the therapeutic approach. METHODS: A systematic literature review was performed utilizing Medline, Embase, SciELO and Lilacs databases. Published studies were identified, reviewed and the data were extracted. RESULTS: Thirty-four studies (69 IBD patients) met inclusion criteria for review. There was inconsistency in reporting of some clinical and therapeutic aspects. Most patients included had Crohn's disease (89.86%), was female (47.83%), had an average age of 27.11 years, and no reported history of psoriasis (84.05%). The patients developed primarily plaque-type psoriasis (40.58%). There was complete remission of psoriatic lesions in 86.96% of IBD patients, existing differences in the therapeutic approaches; cessation of infliximab therapy led to resolution in 47.83% of cases and 43.48% of patients were able to continue infliximab therapy. CONCLUSION: As increasing numbers of IBD patients with psoriasis induced or exacerbated by infliximab, physicians should be aware of its clinical manifestations so that appropriate diagnosis and treatment are properly established. The decision whether to continue or discontinue infliximab should be individualized.

İnflamatuvar barsak hastalığı tanılı olgularımızda ekstraintestinal tutulum tipleri ve sıklığı

“…We determined the frequency of erythema nodosum as 2.3%, and the frequencies of uveitis and primary sclerosing cholangitis as 1.2%, similar to each other. These rates showed similarity with many studies in the literature (8)(9)(10)(11)(12)(13)(14)(15).…”

Expression of Wnt and Notch signaling pathways in inflammatory bowel disease treated with mesenchymal stem cell transplantation: evaluation in a rat model

“…Currently, the conventional medications are salicylic acid, corticosteroids, immunosuppressive agents, and antibiotics [ 3 ]. Although these therapies may offer temporary remission, curative effect is not very obvious, and adverse reactions [ 4 ] such as psoriasis [ 5 ], drug-induced cytotoxicity [ 6 ], and hypersensitivity [ 7 ] may arise in response to treatment.…”

Psoriasis eruptions-like side effects after the use of etanercept: Case report

“…The suspension of the implicated biologic agent is associated with a higher resolution rate, but often the suspension alone is not enough. The suspension of the anti-TNF drug associated with the start of systemic medication for psoriasis resulted in higher cure rates: approximately 64% versus 44% when systemic medications started without suspension of the immunobiological agent (5,12,13). Thus, another type of anti-TNF agent can be used for the treatment of the underlying disease.…”